AcromegalyNews & Research
17 curated articles for Acromegaly — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Pituitary May 13, 2026
Recent progress in the understanding of psychological complications of acromegaly: toward a longitudinal clinical phenotype.
Acromegaly is a chronic endocrine disorder where biochemical remission often fails to ensure psychological recovery. Drawing on cross‑sectional, longitudinal and registry evidence, this paper proposes a longitudinal clinical phenotype to reconcile divergence between hormonal control and patie...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The Journal of clinical endocrinology and metabolism Apr 29, 2026
Diagnosis of Acromegaly.
The clinical presentation of acromegaly reflects systemic effects of chronic GH and IGF-I excess. Diagnostic delay frequently ranges from 6 to 10 years. While classical manifestations such as acral enlargement and facial coarsening are diagnostically important, many patients initially develop nonspe...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The Journal of clinical endocrinology and metabolism Apr 21, 2026
Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors.
Acromegaly is a rare disease usually caused by a pituitary neuroendocrine tumor (PitNET) that produces GH PitNET. PitNETs secreting GH and prolactin (GH&PRL PitNETs) contribute up to 30% to the spectrum of acromegaly and have been attributed a more aggressive behavior. GH&PRL PitNETs can be ...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The Journal of clinical endocrinology and metabolism Apr 15, 2026
Current Controversies in Acromegaly Care.
Persistent disease after surgery for acromegaly is common. Expanding medical management options improves long-term biochemical and clinical outcomes, but controversies in acromegaly care remain. We review literature and provide recommendations regarding accelerating diagnosis, biochemical monitoring...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The Journal of clinical endocrinology and metabolism Apr 11, 2026
Genetics of Familial Acromegaly and Pituitary Gigantism.
The subset of pituitary adenomas with a heritable genetic basis is small but clinically striking. Somatotropinomas are amongst the most frequent pituitary adenoma subtypes encountered in this setting, with germline variants being enriched in familial acromegaly kindreds and people with a childhood o...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The Journal of clinical endocrinology and metabolism Apr 11, 2026
Current Treatment Landscape of Acromegaly.
Treatment of acromegaly includes surgery followed by chronic medical therapy for persistent growth hormone (GH) excess, and, in some patients, radiation. Treatment is aimed at biochemical normalization, which improves survival and comorbidities. However, many patients experience lifelong burden rela...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- Best practice & research. Clinical endocrinology & metabolism Apr 8, 2026
The cross-talk between prolactin and growth hormone in pituitary adenomas.
Coexisting hyperprolactinemia and growth hormone (GH) excess in patients with pituitary adenomas occur in several case scenarios, including tumoral co-secretion of prolactin and GH, stalk effect or medication-induced hyperprolactinemia, and analytical laboratory issues. A correct diagnosis can somet...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The Journal of clinical endocrinology and metabolism Mar 16, 2026
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment.
Paltusotine is a nonpeptide, selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. To evaluate efficacy and safety of paltusotine in patients with biochemically uncontrolled acromegaly not currently receiving medical therapy. In this phase 3, randomize...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The Journal of clinical endocrinology and metabolism Mar 3, 2026
Efficacy and Safety of Pharmacologic Therapies in Acromegaly: A Systematic Literature Review and Network Meta-Analysis.
There are limited head-to-head trials comparing pharmacological treatments for acromegaly. Systematically review the efficacy and safety of pharmacological treatments for acromegaly and conduct a network meta-analysis (NMA) enabling indirect comparisons. MEDLINE and Embase were searched to identify ...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The Journal of clinical endocrinology and metabolism Feb 19, 2026
Facial Analysis in Acromegaly Using Machine Learning: Toward Earlier Diagnosis.
Acromegaly is a rare and progressive disorder often diagnosed late due to its insidious onset and gradually evolving facial features. Early detection remains a critical unmet need to reduce disease-associated morbidity and mortality. This study aimed to develop and evaluate machine learning models t...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The New England journal of medicine Feb 18, 2026
Acromegaly.
Acromegaly.
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The New England journal of medicine Feb 18, 2026
Acromegaly.
Acromegaly.
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The New England journal of medicine Feb 18, 2026
Acromegaly. Reply.
Acromegaly. Reply.
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The New England journal of medicine Feb 18, 2026
Acromegaly.
Acromegaly.
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- The New England journal of medicine Feb 18, 2026
Acromegaly.
Acromegaly.
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- Pituitary Feb 10, 2026
Gamma knife radiosurgery vs fractionated radiotherapy : gender difference in efficacy and toxicity.
Although radiation therapy is used less frequently in the treatment of functioning and nonfunctioning pituitary adenomas, it still plays a role to control volume and secretion. Radiation therapy remains to be considered in the therapeutic algorithm for these diseases, as mentioned in all recent nati...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
- Drugs Jan 31, 2026
Paltusotine: First Approval.
Paltusotine (PALSONIFY™) is a non-hormonal, orally active selective somatostatin receptor 2 (SSTR2) agonist that controls insulin-like growth factor-1 (IGF-1) levels, which are elevated in patients with acromegaly. It is the first approved once daily, orally administered treatment available f...
Why it matters: Recent peer-reviewed research on Acromegaly that may be relevant for patients and caregivers.
More on Acromegaly
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.